RXI PHARMACEUTICALS CORPORATION

Company

SELLAS Life Sciences Group, Inc.

Filed

June 18, 2008

Period of Report

July 18, 2008

Accession Number

0000950135-08-004411

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →